Bio-Techne Corp (TECH) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Bio-Techne Corp stock $50.94, price $72.78, that is 30.0% below the price, quality 78 out of 100. Rating: overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range $43.12 – $131.03 · fair‑value band $37.70 – $63.68 · the $72.78 price screens above the $50.94 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Bio-Techne in your weekly email
Every Wednesday you see whether Bio-Techne is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide.
Show moreShow less
The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology.
The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies.
This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids.
The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications.
The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Stock analysis
Bio-Techne Corp (TECH) currently trades at $72.78, while our model-based Fair Value estimate is $50.94, 30% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $30.68 per share, and 0 of the 26 models we run sit above the $72.78 price.
Bear case: the Economic Profit group reads lowest at $12.37, and 26 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: $37.70 (bear) to $63.68 (bull), the price of $72.78 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 78/100 (high quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Bio-Techne Corp reported revenue of $1.2B in FY2026 versus $1.1B in FY2022, a compound +2.4%/yr. Reported net income was $182M in FY2026, compounding −9.6%/yr from FY2022.
Key figures
Market cap $11.4B Large · P/E ratio 62.7 · P/S ratio 9.30 · EPS (TTM) $1.16 · Dividend yield 0.3% · Net margin 14.0% · Return on equity 8.3% · Return on assets (EBIT) 9.1% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).
What moves the price
The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.
The share trades at its 52-week high and 69% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −30%, TECH screens richer than that median.
Fair Value models
Bear$37.70Fair Value $50.94Bull$63.68
Price $72.78 · Downside -30.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 4 months old). Earnings retained since then ($0.3302 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, no officer or director bought or sold shares on the open market.
SaleAmy E. HerrDirector2× since Feb 17, 2026: 8,612 shares, avg. $50.76$437,187May 8, 2026
Plus 22 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.69/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−0.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.5%
Start year 2021 (pandemic). Over 10 years: +9.3% a year
Revenue growth 37 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.2%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
−3.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year−4.0%
Dividend (yield on the price)0.3%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−4.5% vs 5.2%, slowing
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.26% → 21%
Pace: the 5-year rate starts in 2021 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+24.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+7.7%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +21.7% a year for the price and +5.2% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (93 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
AI conclusion: The business shows potential strength from its expanded GMP production capacity creating an integrated discovery-to-manufacturing workflow, yet its core weakness is the low ROE and ROA reflecting poor capital efficiency.
Main risk: Competitors from low-cost locations and larger players such as Thermo Fisher and Danaher could enter markets more aggressively or consolidate purchasing, forcing Bio-Techne to lower prices or lose reagent and assay customers.
Bull case: Bio-Techne could leverage its proprietary data and AI-designed proteins to deepen integration with cell therapy workflows and broaden its customer base beyond a few large accounts while defending margins through differentiated offerings.
Bear case: If low-cost rivals and large competitors intensify pricing pressure while key cell therapy customers reduce demand or switch suppliers, Bio-Techne's GMP and reagent segments could face sustained margin compression and slower growth.
Bio-Techne just opened a dedicated GMP facility in Bristol for small-molecule production aimed at cell therapy developers, adding to its Minnesota sites and creating an integrated workflow from discovery to manufacturing. The pending Merck KGaA deal looms over these investments. Our models see the shares as overvalued. Will the new capacity accelerate growth under combined ownership or mainly ease the acquirer's integration costs?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 7/15 measures
A mixed picture versus its industry peers.
Valuation
Quality Score78 · Top 25%
Fair Value upside−30.0% · Above median
Profitability
Return on equity (12 months)8.3% · Top 25%
Return on assets6.8% · Top 25%
Net margin (12 months)14.0% · Above median
Operating margin (12 months)13.4% · Above median
Growth and dividend
Revenue growth (quarter YoY)4.6% · Above median
Dividend yield (12 months)0.3% · Bottom 25%
Balance sheet
Debt / equity0.10× · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/E (12 months)62.7× · Priciest 25%
P/B5.42× · Priciest 25%
P/S (12 months)9.30× · Pricier than median
Price / free cash flow (fiscal year)43.4× · Pricier than median
EV/EBITDA34.9× · Priciest 25%
PEG2.18× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)23· sector 0
PAST (return on equity)33· sector 0
HEALTH (low debt)95· sector 97
DIVIDEND (yield)7· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Bio-Techne Corp Fair Value". https://www.fairvalue-calculator.com/stock/TECH
Frequently asked questions
Is Bio-Techne Corp (TECH) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of $50.94 versus a price of $72.78, about 30% lower (overvalued).
What is the fair value of TECH?
Our model-based fair value for Bio-Techne Corp is $50.94 (as of Nov 8, 2026), built from audited fundamentals. The current price: $72.78.
What is the quality score of TECH?
Bio-Techne Corp has a Quality Score of 78/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Bio-Techne Corp (TECH)?
Our model-based price target is the fair value of $50.94 (as of Nov 8, 2026) from 26 valuation models. Cautious scenario $37.70, optimistic scenario $63.68. It is a calculation from audited fundamentals, not an analyst target.
What is the Bio-Techne Corp stock forecast for 2026?
Our models put fair value at $50.94, about 30% lower versus a price of $72.78 (overvalued). Cautious scenario $37.70, optimistic scenario $63.68. The calculation is refreshed regularly with new filings.
What is the revenue of Bio-Techne Corp (TECH)?
Bio-Techne Corp reported trailing-twelve-month revenue of about $1.2B (latest available figure, as of Nov 8, 2026).
Does Bio-Techne Corp pay a dividend?
Bio-Techne Corp currently shows a dividend yield of 0.33% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Bio-Techne Corp (TECH) and when is the ex-dividend date?
Bio-Techne Corp pays a dividend of $0.24 per share a year, a dividend yield of 0.3%. The next ex-dividend date is Nov 13, 2026. A dividend has been paid every year since at least 2008. The payout ratio is 20.7% of earnings. Free cash flow covers the dividend 6.98 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Bio-Techne Corp (TECH)?
For today's price to be fair in a discounted-cash-flow model, Bio-Techne Corp would have to grow free cash flow by +24.6 % per year for five years (discount rate 9.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +5.5 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of TECH use?
Our models discount Bio-Techne Corp at 9.9 %: a base by market capitalisation (large), damped by beta 1.28, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Bio-Techne Corp that is +24.6 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.9 %) and the same formula as our fair value.
How much growth has Bio-Techne Corp (TECH) delivered so far?
Over the past 5 years revenue at Bio-Techne Corp grew +5.5 % a year. The price currently implies free-cash-flow growth of +24.6 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Bio-Techne Corp (TECH) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Bio-Techne Corp (+24.6 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Bio-Techne Corp (TECH)?
The free-cash-flow yield on the price is 2.30 %: that much free cash flow Bio-Techne Corp produces per unit of market value. When it exceeds the discount rate of our models (9.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Bio-Techne Corp (TECH)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Bio-Techne Corp it is $50.94 per share (as of Nov 8, 2026), against a price of $72.78. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Bio-Techne Corp stock overvalued or undervalued in 2026?
As of Nov 8, 2026, TECH trades above its calculated fair value: price $72.78, fair value $50.94, a gap of about −30% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of TECH?
No. The price is what the market pays today ($72.78); the fair value is what the company's own numbers justify ($50.94). For Bio-Techne Corp the two are $21.84 per share apart. That gap is exactly why we show both numbers side by side.
How much is Bio-Techne Corp worth?
The market values Bio-Techne Corp at about $11.4B (market capitalisation, as of Nov 8, 2026). Per share that is $72.78; our models calculate a fair value of $50.94 per share.
What do the bullish and bearish scenarios say about TECH?
Our models span a range for Bio-Techne Corp: cautious scenario $37.70, base $50.94, optimistic $63.68 per share (as of Nov 8, 2026, price $72.78). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of TECH?
Bio-Techne Corp trades at a price-to-earnings ratio of 62.7 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $50.94 is built from several models across several years. Other multiples: PEG 2.2, P/B 5.4, P/S 9.3, EV/EBITDA 34.9.
What is the PEG ratio of TECH?
The PEG ratio of Bio-Techne Corp is 2.18 (P/E divided by earnings growth, as of Nov 8, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Bio-Techne Corp (TECH)?
Balance-sheet figures for Bio-Techne Corp (as of Nov 8, 2026): return on equity 8.3%, debt of 0.10 per unit of equity. They feed the Quality Score of 78/100, which measures business quality independently of the share price.
How far is TECH from its 52-week high?
Bio-Techne Corp trades at $72.78, at its 52-week high of $72.78 and 69% above the low of $43.12 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $50.94 is for.
Which stocks are comparable to Bio-Techne Corp?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Bio-Techne Corp stock attractive at the current price?
The data as of Nov 8, 2026: price $72.78, calculated fair value $50.94 (−30%), Quality Score 78/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of TECH calculated?
We run Bio-Techne Corp through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $50.94 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Bio-Techne Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Bio-Techne Corp (TECH)?
The closing price on Nov 6, 2026 was $72.78. Our model-based fair value is $50.94, about 30% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Bio-Techne Corp right now?
A high-quality business (quality 78/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety. The price sits above even our optimistic bull case ($63.68). The favourable scenario is already priced in.
Where does the earnings growth of Bio-Techne Corp (TECH) come from?
Earnings per share at Bio-Techne Corp grew +3.6 % a year from 2015 to 2026. Broken into its drivers: revenue per share +9.3 %, EBIT margin −6.2 %, tax rate +1.6 %, residual (interest, one-offs) −0.6 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Bio-Techne Corp
How large is the market capitalisation of Bio-Techne Corp (TECH)?
The market capitalisation of Bio-Techne Corp is $11.4B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Bio-Techne Corp (TECH)?
The price-to-sales ratio of Bio-Techne Corp is 9.30 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Bio-Techne Corp (TECH)?
Earnings per share at Bio-Techne Corp are $1.16 (price ÷ EPS = P/E 62.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Bio-Techne Corp (TECH)?
The dividend yield of Bio-Techne Corp is 0.3% (payout 20.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Bio-Techne Corp (TECH)?
The net margin of Bio-Techne Corp is 14.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Bio-Techne Corp (TECH)?
The return on equity (ROE) of Bio-Techne Corp is 8.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Bio-Techne Corp (TECH)?
On an EBIT basis the return on assets of Bio-Techne Corp is 9.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Bio-Techne Corp (TECH)?
The operating margin of Bio-Techne Corp is 13.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Bio-Techne Corp (TECH)?
Revenue at Bio-Techne Corp is growing +4.6% versus a year earlier (3y avg +2.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Bio-Techne Corp (TECH)?
Earnings per share at Bio-Techne Corp are growing −25.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Bio-Techne Corp (TECH) carry?
The net debt of Bio-Techne Corp is $24.4M (fiscal year 2026, ≈ 0.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Bio-Techne Corp in the live analysis
One click puts Bio-Techne Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 8, 2026